source
- Eli Lilly climbs to top of Norstella’s Pipeline-to-Patient Productivity Index, beating 24 peersEli Lilly has risen to the top of Norstella’s inaugural Pipeline-to-Patient Productivity Index, a new benchmark that rates large global biopharma firms on research productivity, market access and c…
- Altimmune’s pemvidutide cuts heavy drinking days in phase 2 AUD trialAltimmune announced that its experimental dual GLP-1/glucagon receptor agonist pemvidutide reduced heavy drinking in a phase‑2 study of alcohol use disorder. In the 24‑week Reclaim trial, particip…